Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

of 85% from THIO and Libtayo. Vlad Vitoc, CEO of MAIA, said: “Treatment with THIO now shows a 99% probability that OS will extend past chemotherapy’s measure by a wide margin. “THIO’s ...

Opens in a new tab or window SAN FRANCISCO -- A combination of cemiplimab (Libtayo) and standard-of-care chemotherapy appeared to be effective in patients with locally advanced or metastatic ...

Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn an additional $0.7 with the CVR.

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

LONDON, GREATER LONDON, UNITED KINGDOM, March 10, 2025 /EINPresswire / -- How Has the Libtayo Market Evolved, and What Are Its Growth Projections? .Market Growth from 2024 to 2025: oThe Libtayo ...

and chemotherapy. The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and Arm 2, evaluating THIO ...